Ironwood Pharmaceuticals Inc 2019 Q1 Institutional Investor Sentiment Better Than Expected

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo

Sentiment for Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)

Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) institutional sentiment increased to 1.37 in Q1 2019. Its up 0.30, from 1.07 in 2018Q4. The ratio is positive, as 74 active investment managers started new or increased stock positions, while 54 reduced and sold their stakes in Ironwood Pharmaceuticals Inc. The active investment managers in our partner’s database now hold: 146.70 million shares, up from 140.64 million shares in 2018Q4. Also, the number of active investment managers holding Ironwood Pharmaceuticals Inc in their top 10 stock positions increased from 2 to 3 for an increase of 1. Sold All: 16 Reduced: 38 Increased: 44 New Position: 30.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $1.40 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

The stock decreased 1.64% or $0.15 during the last trading session, reaching $8.97. About 1.27 million shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 32.56% since August 15, 2018 and is downtrending. It has underperformed by 32.56% the S&P500.

Sarissa Capital Management Lp holds 15.36% of its portfolio in Ironwood Pharmaceuticals, Inc. for 7.54 million shares. Ecor1 Capital Llc owns 4.40 million shares or 5.48% of their US portfolio. Moreover, Bridger Management Llc has 4.48% invested in the company for 4.18 million shares. The Maryland-based Brown Capital Management Llc has invested 1.41% in the stock. Broderick Brian C, a Massachusetts-based fund reported 329,233 shares.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Ratings analysis reveals 25% of Ironwood Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Ironwood Pharma, 1 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $13 while the high is $18. The stock’s average target of $15.25 is 70.01% above today’s ($8.97) share price. IRWD was included in 8 notes of analysts from February 22, 2019. The rating was maintained by H.C. Wainwright on Monday, June 24 with “Hold”. Mizuho maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Friday, February 22 with “Buy” rating. The company was upgraded on Wednesday, March 27 by Morgan Stanley. Credit Suisse maintained it with “Hold” rating and $16 target in Friday, March 22 report. The stock has “Neutral” rating by H.C. Wainwright on Monday, February 25.

More notable recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial – Benzinga” on April 02, 2019, also Businesswire.com with their article: “Ironwood Pharmaceuticals to Present at Cowen Health Care Conference – Business Wire” published on March 04, 2019, Seekingalpha.com published: “Ironwood completes Cyclerion spin-off – Seeking Alpha” on April 01, 2019. More interesting news about Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were released by: Seekingalpha.com and their article: “Ironwood Pharma to offer $330M in senior debt – Seeking Alpha” published on August 06, 2019 as well as Seekingalpha.com‘s news article titled: “Ironwood Pharmaceuticals Q4 2018 Earnings Preview – Seeking Alpha” with publication date: February 12, 2019.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.